Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath?

  • Lee, Jayoung (Department of Radiation Oncology, Pusan National University Yangsan Hospital) ;
  • Lee, Ju Hye (Department of Radiation Oncology, Pusan National University Yangsan Hospital) ;
  • Yoon, Hanbin (Department of Radiation Oncology, Pusan National University Yangsan Hospital) ;
  • Lee, Ho Jeong (Department of Radiation Oncology, Pusan National University Yangsan Hospital) ;
  • Jeon, Hosang (Department of Radiation Oncology, Pusan National University Yangsan Hospital) ;
  • Nam, Jiho (Department of Radiation Oncology, Pusan National University Yangsan Hospital)
  • Received : 2017.05.19
  • Accepted : 2017.05.31
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Primary liver tumor, especially hepatocellular carcinoma (HCC), is a common cause of cancer death worldwide. The incidence is generally higher in Asian countries than in western countries. Carcinogenesis of HCC is often associated with hepatitis viral infections. Current standard treatment of HCC is surgical resection or transplantation in patients with early stage disease. However, the patient with advanced stage disease, surgical resection is often limited. Sorafenib or other treatment modalities are not so effective as well. We report a case of unusual radiation super-sensitivity in advanced stage HCC, and review the literature.

Keywords

References

  1. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6. https://doi.org/10.1097/MCG.0b013e3182872f29
  2. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27. https://doi.org/10.3748/wjg.v20.i15.4115
  3. Ohri N, Dawson LA, Krishnan S, et al. Radiotherapy for hepatocellular carcinoma: new indications and directions for future study. J Natl Cancer Inst 2016;108;djw133. https://doi.org/10.1093/jnci/djw133
  4. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x.
  5. Brade AM, Ng S, Brierley J, et al. Phase 1 Trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2016;94:580-7. https://doi.org/10.1016/j.ijrobp.2015.11.048
  6. Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2014;88:1041-7. https://doi.org/10.1016/j.ijrobp.2014.01.017

Cited by

  1. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma vol.21, pp.4, 2018, https://doi.org/10.3233/cbm-170791
  2. Systematic Analyses of the Role of the Reader Protein of N 6 -Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma vol.7, pp.None, 2017, https://doi.org/10.3389/fmolb.2020.577460
  3. Multiple m 6 A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis vol.20, pp.None, 2017, https://doi.org/10.1186/s12885-020-6638-5